Abstract bekijken

Deze abstract is toegekend aan sessies
TitelOzurdex implant migration into the Anterior chamber
DoelOzurdex (Allergan Inc, Irvine, CA, USA) is a biodegradable sustained release device containing 0.7 mg of dexamethasone in a solid polymer drug delivery system. It is approved for the management of macular oedema associated with central and branch retinal vein occlusion, diabetic macular oedema and non-infectious uveitis. With increasing use of this non-tethered steroid implant we continue to learn about potential risks associated with the treatment and thus learn about considerations prior to starting such a treatment and also how to manage such complications should they arise.
MethodesHere we present a case of a 61 year old male who unfortunately developed one of the rarer complications of an Ozurdex implant. 11 days following the implant, the patient noticed the implant in the anterior chamber of his eye leading to corneal endothelium decompensation, and thus the deterioration in his vision
Resultatenthe patient continued to have corneal oedema due to endothelial cell loss
ConclusieWe review the risk factors of Ozurdex implant migration, and how to manage the patients that develop such a complication
BelangenverstrengelingNee
Auteur 1
NaamNARDEOSINGH
InitialenS
InstituutOphthalmology
StadGlasgow
Auteur 2
NaamElhassan
InitialenS
InstituutOphthalmology
StadCardiff
Auteur 3
NaamWilliams
InitialenG
InstituutOphthalmology
StadSwansea
Auteur 4
NaamHill
InitialenR
InstituutOphthalmology
StadSwansea
top ^